21 CFR 211.165
Testing and release for distribution
- Inspections citing it: 1,899
- Of those classified, ended OAI: 40%
- Last cited: FY2026
Inspections Citing It by Fiscal Year
Sites in and outside the US, FY2017 to Oct 20, 2026.
Paragraphs Cited
As FDA posts them, all years.
- 211.165(a)
- 850 · Testing and release for distribution
- 211.165(e)
- 401 · Test methods
- 211.165(b)
- 264 · Microbiological testing
- 211.165(f)
- 176 · Failing drug products not rejected
- 211.165(d)
- 119 · Acceptance criteria for sampling & testing
- 211.165(c)
- 89 · Sampling and testing plans not described
Regulation Text
eCFR did not answer; open it on eCFRRecently Cited Sites
Newest inspections citing this section; each opens the site- Nowcos Co., Ltd.Unknown · Jun 19, 2026
- Product Society LLCUnited States · Jun 12, 2026
- Inspec Solutions LLCUnited States · Jun 12, 2026
- Cosmoceutical Research Center, Inc.United States · May 29, 2026
- Unither Manufacturing LLC.United States · May 15, 2026
- Topical Pharmaceuticals, Inc.United States · May 7, 2026
- GVS TM, IncUnited States · May 1, 2026
- New SPS Crossfolds, LLCUnited States · Apr 20, 2026
- Baxter Healthcare CorporationUnited States · Apr 2, 2026
- Allure Labs, LLCUnited States · Mar 27, 2026
- Dr. J Skinclinic, IncUnited States · Mar 23, 2026
- Gasco Industrial Corp.United States · Feb 27, 2026
Counts are inspections with posted citations that cite any paragraph of the section, once per inspection, from FDA's Data Dashboard. OAI share is over inspections FDA finally classified. Text from eCFR, the official online CFR. FDA Data Dashboard and eCFR